These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 32994152

  • 1. Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis.
    Perera K, Kam N, Ademi Z, Liew D, Zomer E.
    J Clin Lipidol; 2020; 14(6):772-783. PubMed ID: 32994152
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
    Nicholls S, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, Libby P, Moriarty PM, Plutzky J, Ray KK, Thompson PD, Sasiela W, Mason D, McCluskey J, Davey D, Wolski K, Nissen SE.
    Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs.
    Lincoff AM, Ray KK, Sasiela WJ, Haddad T, Nicholls SJ, Li N, Cho L, Mason D, Libby P, Goodman SG, Nissen SE.
    J Am Coll Cardiol; 2024 Jul 09; 84(2):152-162. PubMed ID: 38960508
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bempedoic Acid: A New Drug for an Old Problem.
    Nguyen D, Du N, Sulaica EM, Wanat MA.
    Ann Pharmacother; 2021 Feb 09; 55(2):246-251. PubMed ID: 32674598
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS.
    JAMA Cardiol; 2017 Oct 01; 2(10):1069-1078. PubMed ID: 28832867
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of Bempedoic Acid in Dyslipidemia Management.
    Kelly MS, Sulaica EM, Beavers CJ.
    J Cardiovasc Pharmacol; 2020 Oct 01; 76(4):376-388. PubMed ID: 32732494
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
    Bays HE, Bloedon LT, Lin G, Powell HA, Louie MJ, Nicholls SJ, Lincoff AM, Nissen SE.
    J Clin Lipidol; 2024 Oct 01; 18(1):e59-e69. PubMed ID: 37951797
    [Abstract] [Full Text] [Related]

  • 19. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
    Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J.
    Clin Ther; 2008 Aug 01; 30(8):1508-23. PubMed ID: 18803993
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.